Background
==========

Myeloid related protein (MRP)8 and MRP14 are released by early monocytes upon contact with activated endothelium and correlate with inflammation in rheumatoid arthritis (RA) and juvenile arthritis.

Objective
=========

The aim of the study was to investigate serum MRP8/MRP14 as biomarker for inflammation in chronic arthritis.

Methods
=======

The study included 40 RA patients with active joint involvement (SJC = 14, CRP = 2.4 mg/dl, ESR = 28 mm/hour); 30 SpA patients with peripheral synovitis (SJC = 2, CRP = 2.2 mg/dl, ESR = 21 mm/hour); 10 AS patients with exclusive axial involvement (SJC = 0, CRP = 3.1 mg/dl, ESR = 19 mm/hour); and 20 healthy controls (HC). In 20 RA, 10 peripheral SpA and 10 axial AS patients, sera were also obtained after 6 weeks of infliximab therapy. Serum MRP8/MRP14 was measured by ELISA.

Results
=======

MRP8/MRP14 was increased in RA (1075 ng/ml; *P*\< 0.001), peripheral SpA (815 ng/ml; *P*\< 0.001) and axial AS (710 ng/ml; *P*\< 0.001), as compared with HC (280 ng/ml). In patients with peripheral synovitis, MRP8/MRP14 correlated with CRP (RA, *r*= 0.77, *P*\< 0.001; peripheral SpA, *r*= 0.69, *P*\< 0.001) and ESR (RA, *r*= 0.70, *P*\< 0.001; peripheral SpA, *r*= 0.62, *P*= 0.001). MRP8/MRP14 decreased after infliximab in RA (*P*\< 0.001), peripheral SpA (*P*= 0.009) and axial AS (*P*= 0.012). Of 9/40 RA, 6/30 peripheral SpA and 1/10 axial AS patients with CRP \< 1 mg/dl, only one peripheral SpA patient had increased MRP8/MRP14 (\> mean MRP8/MRP14 in HC + 2SD). Of 17/40 RA, 12/30 peripheral SpA and 6 axial AS patients with ESR \< 20 mm/hour, 3/17 RA, 6/12 peripheral SpA and 3/6 axial AS patients had raised MRP8/MRP14. Finally, we assessed the sensitivity to change after infliximab. In RA and peripheral SpA, changes in MRP8/MRP14 were not different from changes in CRP and ESR, whereas in axial AS changes in MRP8/MRP14 were less pronounced than changes in ESR (*P*= 0.005).

Conclusion
==========

Raised MRP8/MRP14 levels, correlations with CRP and ESR, and decrease after infliximab confirm that serum MRP8/MRP14 reflect inflammation. Further research is warranted to assess the added value of MRP8/MRP14 as compared with CRP and ESR.
